Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 8/20 | 0.45 |
| ▸ | HTT | P42858 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880150 | 1.00 | GAA (0.49) | GAAPKMLMNAHTTMAPT | |
| SCHEMBL5879733 | 0.91 | GAA (0.50) | GAAPKMLMNAHTTMAPT | |
| SCHEMBL5879730 | 0.91 | GAA (0.50) | GAAPKMLMNAHTTMAPT | |
| SCHEMBL5880006 | 0.90 | LMNA (0.48) | GAALMNAHTTMAPTMEN1 | |
| SCHEMBL5880004 | 0.90 | LMNA (0.48) | GAALMNAHTTMAPTMEN1 | |
| SCHEMBL6372701 | 0.85 | MEN1 (0.53) | GAALMNAHTTMAPTMEN1 | |
| SCHEMBL5879660 | 0.85 | MEN1 (0.53) | GAALMNAHTTMAPTMEN1 | |
| SCHEMBL5879887 | 0.84 | MEN1 (0.50) | GAALMNAHTTMAPTMEN1 | |
| SCHEMBL6378130 | 0.84 | MEN1 (0.50) | GAALMNAHTTMAPTMEN1 | |
| SCHEMBL5880132 | 0.84 | LMNA (0.48) | GAALMNAHTTMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026339-B2 | Inhibitors of HCV NS5B polymerase | PFIZER INC. | 2006-04-11 | — | — | US | disclosed |
| US-20050154056-A1 | [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate | PHARMACIA & UPJOHN COMPANY | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154056-A1 | [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate | ACACB, HCCS, HAVCR2 | GAA 1027/4885PKM 3565/4885LMNA 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.